Meta‐analysis: reduction in hepatic events following interferon‐alfa therapy of chronic hepatitis B

Aliment Pharmacol Ther 2010; 32: 1059–1068 Summary Background  The long‐term benefit of interferon‐alfa (IFN‐α) treatment in preventing various hepatic complications is not certain. Aim  To study the effects of IFN‐α on reducing the risk of developing overall hepatic events (hepatocellular carcinoma...

Full description

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2010-11, Vol.32 (9), p.1059-1068
Main Authors: Wong, G. L.‐H., Yiu, K. K.‐L., Wong, V. W.‐S., Tsoi, K. K.‐F., Chan, H. L.‐Y.
Format: Article
Language:English
Subjects:
alpha -Interferon
Biological and medical sciences
Carcinoma, Hepatocellular - etiology
Carcinoma, Hepatocellular - prevention & control
Clinical trials
Conferences
Digestive system
Gastroenterology. Liver. Pancreas. Abdomen
Hepatitis B
Hepatitis B, Chronic - complications
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - pathology
Hepatocellular carcinoma
Human viral diseases
Humans
Infectious diseases
Interferon-alpha - therapeutic use
Liver Neoplasms - prevention & control
Medical sciences
Mortality
Pharmacology. Drug treatments
Randomized Controlled Trials as Topic
Reviews
Risk assessment
Statistics as Topic
Treatment Outcome
Viral diseases
Viral hepatitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aliment Pharmacol Ther 2010; 32: 1059–1068 Summary Background  The long‐term benefit of interferon‐alfa (IFN‐α) treatment in preventing various hepatic complications is not certain. Aim  To study the effects of IFN‐α on reducing the risk of developing overall hepatic events (hepatocellular carcinoma, cirrhotic complications and liver‐related mortality) in chronic hepatitis B patients. Methods  Randomized controlled trials, case–control studies and cohort studies were retrieved from electronic databases and conference s. Relative risks (RRs) of different hepatic complications among patients treated by IFN‐α vs. no treatment or placebo were studied. Results  Eleven studies were identified totalling 975 patients treated by IFN‐α vs. 1147 untreated controls for analysis. Patients were treated by IFN‐α for 1–24 months with a post‐treatment follow‐up of 1–13 years. Treatment by IFN‐α reduced the risk of overall hepatic events (RR 0.55, 95% confident interval or CI 0.43–0.70, P 
ISSN:0269-2813
1365-2036
DOI:10.1111/j.1365-2036.2010.04447.x